181 related articles for article (PubMed ID: 21428921)
21. The cellular response to ectopic overexpression of the tuberous sclerosis genes, TSC1 and TSC2: a proteomic approach.
Hengstschläger M; Rosner M; Fountoulakis M; Lubec G
Int J Oncol; 2005 Sep; 27(3):831-8. PubMed ID: 16077935
[TBL] [Abstract][Full Text] [Related]
22. Platelet-derived growth factor-induced p42/44 mitogen-activated protein kinase activation and cellular growth is mediated by reactive oxygen species in the absence of TSC2/tuberin.
Finlay GA; Thannickal VJ; Fanburg BL; Kwiatkowski DJ
Cancer Res; 2005 Dec; 65(23):10881-90. PubMed ID: 16322235
[TBL] [Abstract][Full Text] [Related]
23. Emerging treatments in the management of tuberous sclerosis complex.
Kohrman MH
Pediatr Neurol; 2012 May; 46(5):267-75. PubMed ID: 22520346
[TBL] [Abstract][Full Text] [Related]
24. The tuberous sclerosis genes and regulation of the cyclin-dependent kinase inhibitor p27.
Rosner M; Freilinger A; Hengstschläger M
Mutat Res; 2006 Sep; 613(1):10-6. PubMed ID: 16713332
[TBL] [Abstract][Full Text] [Related]
25. Cardiac rhabdomyomas in tuberous sclerosis complex show apoptosis regulation and mTOR pathway abnormalities.
Kotulska K; Larysz-Brysz M; Grajkowska W; Jóźwiak J; Włodarski P; Sahin M; Lewin-Kowalik J; Domańska-Pakieła D; Jóźwiak S
Pediatr Dev Pathol; 2009; 12(2):89-95. PubMed ID: 17990907
[TBL] [Abstract][Full Text] [Related]
26. Tuberous sclerosis genes regulate cellular 14-3-3 protein levels.
Hengstschläger M; Rosner M; Fountoulakis M; Lubec G
Biochem Biophys Res Commun; 2003 Dec; 312(3):676-83. PubMed ID: 14680818
[TBL] [Abstract][Full Text] [Related]
27. Renal tumours in a Tsc1+/- mouse model show epigenetic suppression of organic cation transporters Slc22a1, Slc22a2 and Slc22a3, and do not respond to metformin.
Yang J; Kalogerou M; Gallacher J; Sampson JR; Shen MH
Eur J Cancer; 2013 Apr; 49(6):1479-90. PubMed ID: 23228442
[TBL] [Abstract][Full Text] [Related]
28. A genetic model to dissect the role of Tsc-mTORC1 in neuronal cultures.
Nie D; Sahin M
Methods Mol Biol; 2012; 821():393-405. PubMed ID: 22125080
[TBL] [Abstract][Full Text] [Related]
29. Tuberous sclerosis complex, implication from a rare genetic disease to common cancer treatment.
Inoki K; Guan KL
Hum Mol Genet; 2009 Apr; 18(R1):R94-100. PubMed ID: 19297407
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic targeting of mTOR in tuberous sclerosis.
Sampson JR
Biochem Soc Trans; 2009 Feb; 37(Pt 1):259-64. PubMed ID: 19143643
[TBL] [Abstract][Full Text] [Related]
31. Tuberous sclerosis.
Curatolo P; Bombardieri R; Jozwiak S
Lancet; 2008 Aug; 372(9639):657-68. PubMed ID: 18722871
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of a rapamycin analog (CCI-779) and IFN-gamma in tuberous sclerosis mouse models.
Lee L; Sudentas P; Donohue B; Asrican K; Worku A; Walker V; Sun Y; Schmidt K; Albert MS; El-Hashemite N; Lader AS; Onda H; Zhang H; Kwiatkowski DJ; Dabora SL
Genes Chromosomes Cancer; 2005 Mar; 42(3):213-27. PubMed ID: 15578690
[TBL] [Abstract][Full Text] [Related]
33. Analysis of 65 tuberous sclerosis complex (TSC) patients by TSC2 DGGE, TSC1/TSC2 MLPA, and TSC1 long-range PCR sequencing, and report of 28 novel mutations.
Rendtorff ND; Bjerregaard B; Frödin M; Kjaergaard S; Hove H; Skovby F; Brøndum-Nielsen K; Schwartz M;
Hum Mutat; 2005 Oct; 26(4):374-83. PubMed ID: 16114042
[TBL] [Abstract][Full Text] [Related]
34. Rapamycin as a therapy of choice after renal transplantation in a patient with tuberous sclerosis complex.
Tarasewicz A; Debska-Slizień A; Konopa J; Zdrojewski Z; Rutkowski B
Transplant Proc; 2009 Nov; 41(9):3677-82. PubMed ID: 19917366
[TBL] [Abstract][Full Text] [Related]
35. The tuberous sclerosis genes, TSC1 and TSC2, trigger different gene expression responses.
Rosner M; Freilinger A; Lubec G; Hengstschläger M
Int J Oncol; 2005 Nov; 27(5):1411-24. PubMed ID: 16211238
[TBL] [Abstract][Full Text] [Related]
36. Functional assessment of variants in the TSC1 and TSC2 genes identified in individuals with Tuberous Sclerosis Complex.
Hoogeveen-Westerveld M; Wentink M; van den Heuvel D; Mozaffari M; Ekong R; Povey S; den Dunnen JT; Metcalfe K; Vallee S; Krueger S; Bergoffen J; Shashi V; Elmslie F; Kwiatkowski D; Sampson J; Vidales C; Dzarir J; Garcia-Planells J; Dies K; Maat-Kievit A; van den Ouweland A; Halley D; Nellist M
Hum Mutat; 2011 Apr; 32(4):424-35. PubMed ID: 21309039
[TBL] [Abstract][Full Text] [Related]
37. Pulmonary lymphangioleiomyomatosis (LAM): progress and current challenges.
Goncharova EA; Krymskaya VP
J Cell Biochem; 2008 Feb; 103(2):369-82. PubMed ID: 17541983
[TBL] [Abstract][Full Text] [Related]
38. The tuberous sclerosis complex genes in tumor development.
Mak BC; Yeung RS
Cancer Invest; 2004; 22(4):588-603. PubMed ID: 15565817
[TBL] [Abstract][Full Text] [Related]
39. Deficient TSC1/TSC2-complex suppression of SOX9-osteopontin-AKT signalling cascade constrains tumour growth in tuberous sclerosis complex.
Jin F; Jiang K; Ji S; Wang L; Ni Z; Huang F; Li C; Chen R; Zhang H; Hu Z; Zha X
Hum Mol Genet; 2017 Jan; 26(2):407-419. PubMed ID: 28013293
[TBL] [Abstract][Full Text] [Related]
40. Comparative analysis of Tsc1 and Tsc2 single and double radial glial cell mutants.
Mietzsch U; McKenna J; Reith RM; Way SW; Gambello MJ
J Comp Neurol; 2013 Nov; 521(16):3817-31. PubMed ID: 23749404
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]